IAN FUND is a unique early stage fund. Over the years, IAN has become a revolution in the angel investment space. The logical next step was to create country’s largest horizontal platform for seed/early stage investments. With a customer & enterprise focus, leveraging India’s technology strengths & growing consumer markets the focus is now to turn around Long term commitment on seed / early stage.

IAN Fund

KITVEN Fund is a venture capital fund backed by state & central government financial institutions operating in the State of Karnataka.

Karnataka Information Technology Venture Capital Fund

Started in April 2006, the Indian Angel Network is a unique concept which brings together highly successful entrepreneurs and CEOs from India and around the world who are interested in investing in startup / early stage ventures which have the potential of creating disproportionate value.  The Network, in addition to money, provide constant access to high quality mentoring, vast networks and inputs on strategy as well as execution. The Network members, because of their background are better able to assess the potential and risks at the early stage.

IAN Group

500 Global is a multi-stage venture capital firm with $2.4 billion in assets under management. The firm invests in founders who are building fast-growing technology companies. It focuses on markets where technology, innovation, and capital can generate long-term value and economic growth. 500 Global collaborates with key stakeholders and provides advisory services to governments on fostering entrepreneurial ecosystems to support startups. The firm has invested in over 5,000 founders and more than 2,800 companies across 80+ countries. It has funded over 35 companies valued at more than $1 billion and over 160 companies valued at over $100 million, including those that are private, public, or have exited. The team consists of over 190 members based in more than 25 countries, with experience as entrepreneurs, investors, and operators from leading technology companies.

500 Global

021 Capital is an early-stage technology VC focused on SAAS, EdTech, Fintech, Tech enablement, and Retail tech among others.

021 Capital

This story is of Mukesh Kumar and his wife Rukmani from Aligarh, who with their dedication and hard work have made a mark in the society. It is said that for a successful person, self-confidence is a must which Mukesh and Rukmani had. The only issue was that they did not have access to money and the right guidance. In that process, they met the Centre Manager of Capital Trust Limited and informed that they were having a small business of Cosmetics.

Capital Trust

BTB Venture is a presales outsourcing and marketing agency.

BTB Venture

Kotak Alternate Asset Managers is a real estate investment arm of Kotak Mahindra Bank Limited specializing in investments in infrastructure projects in India. The firm seeks to invest in power generation, transmission, transport and infrastructure projects, and infrastructure-holding companies. Kotak Investment Advisors Ltd. is based in Mumbai, India.

Kotak Alternate Asset Managers

Karnataka Trustee

Everest Finance And Investments Private Limited is a private unlisted Non-Government Company.

EVEREST FINANCE AND INVESTMENTS PRIVATE LIMITED

Pandorum Technologies

Pandorum Technologies Pvt. Ltd. is a Bangalore based biotechnology company with focus on tissue engineering and regenerative medicine. With its distinct synergy of life science, engineering and clinical competences, the company designs and manufactures three dimensional functional human tissues; intended for medical research and therapeutics. Pandorum Technologies is supported by the Biotechnology Industry Research Assistance Council, Department of Biotechnology, GoI. Pandorum’s labs are presently located in the Center for Cellular and Molecular Platforms, National Centre for Biological Sciences campus, Bengaluru, and in the Bangalore Bioinnovation Centre, Biotech Park, Electronics City Phase 1, Bengaluru.

Pandorum Technologies is a biotechnology company focusing on tissue engineering and regenerative medicine. The company develops therapeutic products aimed at alleviating health conditions related to corneal dystrophies, lung disorders, and liver diseases. Pandorum's flagship product, Kuragenx, is a regenerative therapy for corneal blindness that combines proprietary biomaterials with regenerative nanotherapy to guide the formation of functional corneal tissue, thereby restoring vision. This first-in-class approach blurs the line between treatment and cure.

Pandorum Technologies secures USD 11 million investment to advance its regenerative therapy for corneal blindness to clinical phase

Wipro partners with Pandorum to accelerate Regenerative Medicine with AI

Pandorum Technologies Raises USD 11M in Funding

Careers – Pandorum Technologies

Pandorum Technologies Pvt. Ltd. » Company Directory

Wipro and Pandorum Partner to Accelerate Regenerative Medicine with AI

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Wipro

To leverage Wipro Holmes' Artificial Intelligence capabilities and Pandorum’s expertise in tissue engineering and regenerative medicine to expedite the development of advanced therapeutics, particularly focusing on the bio-engineered liquid cornea, and to enhance patient outcomes through innovative R&D and clinical trials.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Pandorum Technologies is a biotechnology company focusing on tissue engineering and regenerative medicine. The company develops therapeutic products aimed at alleviating health conditions related to corneal dystrophies, lung disorders, and liver diseases. Pandorum's flagship product, Kuragenx, is a regenerative therapy for corneal blindness that combines proprietary biomaterials with regenerative nanotherapy to guide the formation of functional corneal tissue, thereby restoring vision. This first-in-class approach blurs the line between treatment and cure.
In extensive preclinical studies, Kuragenx has demonstrated the ability to promote scarless regeneration of corneal tissue. In March 2023, it received Orphan Drug Designation from the US FDA for treating neurotrophic keratitis, a severe form of corneal blindness. Pandorum is engaged in clinical manufacturing processes and enabling studies for Kuragenx, with the aim of conducting the first patient dosing in 2025, pending regulatory approvals.
Beyond the cornea, Pandorum's tunable technology platform has shown regenerative potential for liver, lung, and neuronal tissues. The company has developed 3D bioprinted vascularized organoids and organ patches intended for medical research, drug screening, disease modeling, and therapeutic applications.
Pandorum has research and development facilities in Bengaluru, India, and the San Francisco Bay Area. It has received competitive grants from the Department of Biotechnology, Government of India. In March 2024, the company secured USD 11 million in pre-Series B funding to advance Kuragenx's clinical development.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

Developing software solutions and applications for designing and managing the bioprinting production process.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Pandorum Technologies

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless